Eli Lilly’s stock rose over 2% on Tuesday, buoyed by optimism surrounding its obesity drug orforglipron, which may receive FDA approval by year-end, as reported by Reuters. This gain occurred despite the S&P 500 index closing slightly lower, along with news of the company’s manufacturing expansion capabilities.
